Skip to main content
. 2021 Apr 1;203(7):831–840. doi: 10.1164/rccm.202004-0993OC

Figure 2.

Figure 2.

Incidence rate ratios and 95% confidence intervals (CIs) for asthma exacerbations and asthma symptom encounters among patients with type 2 diabetes. Users of SGLT-2 (sodium–glucose cotransporter-2) inhibitors, DPP-4 (dipeptidyl peptidase-4) inhibitors, sulfonylureas, and basal insulins were compared with GLP-1R (glucagon-like peptide-1 receptor) agonist users (reference group). (A) GLP-1R agonist users have fewer asthma exacerbations compared with all comparator cohorts. Asthma exacerbations incidence rate ratios and 95% CIs are derived from zero-inflated Poisson regression models. (B) GLP-1R agonist users have fewer asthma symptoms compared with DPP-4 inhibitor, sulfonylurea, and basal insulin groups. Asthma symptom encounter incidence rate ratios and 95% CIs are derived from zero-inflated Poisson regression models. ref = reference.